United Therapeutics Corporation (BVMF:U2TH34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 121.57B +71.1% |
| Revenue (ttm) | 16.54B +5.9% |
| Net Income | 6.72B +6.3% |
| EPS | 141.19 +7.8% |
| Shares Out | n/a |
| PE Ratio | 18.10 |
| Forward PE | 17.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 139.40 |
| Previous Close | 139.60 |
| Day's Range | 137.50 - 139.40 |
| 52-Week Range | 79.04 - 155.07 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About United Therapeutics
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial numbers in USD Financial StatementsNews
United Therapeutics acquires Thymmune Therapeutics
United Therapeutics (UTHR) has acquired Thymmune Therapeutics, a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treat...
United Therapeutics Corporation Acquires Thymmune Therapeutics
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately h...
FDA premarket approval of LungFX positive for United Therapeutics, says Leerink
Leerink views the FDA’s premarket approval of LungFX as “an incremental positive” for United Therapeutics (UTHR) and the transplantation space overall, the analyst tells investors. The approval repres...
United Therapeutics announces FDA approval of the LungFX device
United Therapeutics (UTHR) announced that the U.S. FDA has granted premarket approval of the LungFX device for use in centralized ex vivo lung perfusion, a procedure that enables donor lungs…
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics Transcript: AGM 2026
The virtual annual meeting marked the company's 30th anniversary, with all director nominees elected and all shareholder proposals approved. No questions were raised by shareholders, and voting results will be reported in a forthcoming SEC filing.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
United Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Multiple late-stage clinical successes in IPF and PAH are driving confidence in achieving a $1 billion quarterly run rate by 2027, with further revenue growth expected from new indications and product launches. Expansion of the sales force and ongoing pivotal trials in PPF and xenotransplantation support a robust long-term outlook.
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov...
United Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Significant clinical progress in IPF and PAH is expected to drive revenue growth, with TYVASO and ralinepag positioned for major label expansions. Regulatory filings and new product launches are on track, while organ manufacturing programs advance toward addressing unmet needs.
United Therapeutics says TETON-1 study published in NEJM
United Therapeutics (UTHR) Corporation announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and…
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medici...
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCO...
United Therapeutics cleared by FDA to proceed with UHeart clinical trial
United Therapeutics (UTHR) announced that the U.S. FDA has granted clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart der...
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics, Varda Space Industries team on use of microgravity
Varda Space Industries announced a collaboration with United Therapeutics (UTHR) to explore the use of microgravity to develop improved formulations of treatments for rare pulmonary disease. Through t...
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov...
United Therapeutics to present positive data of treprostinil in IPF
United Therapeutics (UTHR) announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society International Conference, May 15-...
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across ...
United Therapeutics price target lowered to $516 from $519 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on United Therapeutics (UTHR) to $516 from $519 and keeps an Equal Weight rating on the shares. Published first on…
United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded United Therapeutics (UTHR) to Overweight from Equal Weight with a $738 price target
United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded United Therapeutics (UTHR) to Overweight from Equal Weight with a price target of $735, up from $575. The firm says Ralinepag DPI brings confidence in United Therapeutics’…
United Therapeutics reports Q1 EPS $5.82, consensus $6.86
Reports Q1 revenue $781.5M, consensus $797.38M. “In Q1, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies,” said CEO Martine Rothblatt.
United Therapeutics reports Q1 EPS $5.82, consensus $6.86
Reports Q1 revenue $781.5M, consensus $797.38M. “In Q1, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies,” said CEO Martine Rothblatt.